This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Brown, M. J Search for Related Content PubMed Articles by Brown, M. J Social Bookmarking                   What's this?

Direct renin inhibition — a new way of targeting the renin system

University of Cambridge, Addenbrooke's Hospital, Cambridge, UK, mjb14{at}medschl.cam.ac.uk

The renin system plays a key role in the pathology of hypertension and is influenced, both directly and indirectly, by most antihypertensive agents. The system is the target of several established classes of antihypertensive agents including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and beta-blockers. Of currently available drugs, only the beta-blockers suppress renin secretion, but these also reduce heart rate and cardiac output. Calcium channel blockers and diuretics cause a modest activation of the renin system secondary to the fall in renal afferent arteriolar pressure and reduction in filtered sodium load. Aliskiren is the first orally available direct inhibitor that blocks the renin system at its rate limiting step and is shown to reduce angiotensin I and II and plasma renin activity.

Key Words: renin • aliskiren • direct renin inhibitors

Journal of Renin-Angiotensin-Aldosterone System, Vol. 7, No. 2 suppl, S7-S11 (2006)
DOI: 10.3317/jraas.2006.035


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?